Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $2.8 billion.

  • Takeda Pharmaceutical's Short-term Investments rose 534.48% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 billion, marking a year-over-year increase of 534.48%. This contributed to the annual value of $2.3 billion for FY2025, which is 210309.58% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Short-term Investments stood at $2.8 billion, which was up 534.48% from $2.5 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Short-term Investments' 5-year high stood at $2.8 billion during Q4 2025, with a 5-year trough of $101.8 million in Q1 2024.
  • Its 5-year average for Short-term Investments is $1.8 billion, with a median of $2.2 billion in 2021.
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 3702.39% in 2022, then soared by 216039.29% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Short-term Investments stood at $2.0 billion in 2021, then fell by 3.91% to $1.9 billion in 2022, then fell by 6.31% to $1.8 billion in 2023, then skyrocketed by 43.36% to $2.6 billion in 2024, then increased by 5.34% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q4 2025, $2.5 billion for Q3 2025, and $2.3 billion during Q2 2025.